Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Status:
RECRUITING
Trial end date:
2027-01-08
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
City of Hope Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
ARQ531 Biopsy CT-P10 Magnetic Resonance Spectroscopy Rituximab Specimen Handling